4.1 Clinical heart failure |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.06, 15.48] |
4.2 Adverse effects other than cardiac damage |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
4.2.1 Anaemia grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
2.91 [0.79, 10.70] |
4.2.2 Leukopenia grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
1.06 [0.75, 1.49] |
4.2.3 Neutropenia grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
1.05 [0.84, 1.31] |
4.2.4 Febrile neutropenia grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
0.78 [0.47, 1.31] |
4.2.5 Thrombocytopenia grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
12.62 [0.71, 223.52] |
4.2.6 Nausea/vomiting grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
0.91 [0.45, 1.82] |
4.2.7 Fatigue grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
0.32 [0.07, 1.60] |
4.2.8 Infection grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
0.79 [0.48, 1.31] |
4.2.9 Central nervous system grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
2.91 [0.12, 71.35] |
4.2.10 Pulmonary grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
2.91 [0.12, 71.35] |
4.2.11 Peripheral neuropathy grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
4.50 [2.37, 8.54] |
4.2.12 Hepatotoxicity grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
1.70 [0.50, 5.77] |
4.2.13 Hypersensitivity reactions grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
3.88 [1.71, 8.82] |
4.2.14 Mucositis grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
1.05 [0.48, 2.28] |
4.2.15 Pain grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
0.32 [0.01, 7.93] |
4.2.16 Arthralgias/myalgias grade 3 or 4 |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
3.88 [1.31, 11.54] |
4.2.17 Treatment‐related death |
1 |
1086 |
Risk Ratio (M‐H, Random, 95% CI) |
2.91 [0.12, 71.35] |